To test whether the generalized MLR is able to predict CD274 levels in cancer types other than BRCA, LUAD, or SKCM, we used data from a total of 36 patients with cholangiocarcinoma (CHOL), and 165 patients with rectum adenocarcinoma (READ) (Supplementary file S1, Table S3). Here, CD274 is linked to cancer.